Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: A 12-week open-label study

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 588-595

  Chen, Jun ^a,b   Muzina, David J ^c,d   Kemp, David E ^b   Conroy, Carla ^b   Chan, Philip ^b   Serrano, Mary Beth ^b   Ganocy, Stephen J ^b   Fang, Yiru ^a   Calabrese, Joseph R ^b   Gao, Keming ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Medco Health Solutions   (United States)

Author keywords

bipolar disorder; olanzapine; safety; second generation antipsychotic; treatment outcome; treatment resistant mania

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; HALOPERIDOL; LITHIUM CARBONATE; LORAZEPAM; MESORIDAZINE; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ACUTE DISEASE; ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HUMAN; MALE; MASTALGIA; MONOTHERAPY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REMISSION; SEDATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YOUNG MANIA RATING SCALE;

ADULT; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 83855165655     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1249     Document Type: Article

References (51)

1. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al,. 2010. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 11: CD006633.
2. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL,. 2003. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 23: 342-348.
3. Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al,. 2008. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 159: 250-253.
4. Barnes TR,. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
5. Barton BM, Gitlin MJ,. 1987. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol. 7: 101-103.
6. Bitter I, Dossenbach MR, Brook S, et al,. 2004. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 173-180.
7. Burt T, Sachs GS, Demopulos C,. 1999. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 45: 959-964.
8. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, et al,. 1997. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 58 (Suppl 10): 28-36.
9. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY,. 1996. Clozapine for treatment-refractory mania. Am J Psychiatry 153: 759-764.
10. Chan HY, Jou SH, Juang YY, Chang CJ, Chen JJ, Chen CH, et al,. 2010. A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania. Psychiatry Clin Neurosci. 64: 162-169.
11. Das S, Fowler SC,. 1996. Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior. Psychopharmacology (Berl). 123: 374-378.
12. Deveney AM, Waddington JL,. 1996. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213. Psychopharmacology (Berl). 124: 40-49.
13. Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G,. 2006. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord. 8: 75-80.
14. Fava M, Rush AJ, Wisniewski SR, et al,. 2006. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163: 1161-1172.
15. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al,. 2000. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 61: 9-15.
16. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR,. 2008. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28: 203-209.
17. Gitlin M,. 2006. Treatment-resistant bipolar disorder. Mol Psychiatry 11: 227-240.
18. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, et al,. 2000. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 157: 982-986.
19. Haddad PM, Sharma SG,. 2007. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 21: 911-936.
20. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
21. Kang X, Simpson GM,. 2010. Clozapine: more side effects but still the best antipsychotic. J Clin Psychiatry. 71: 982-983.
22. Kay SR, Fiszbein A, Opler LA,. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
23. Kramlinger KG, Post RM,. 1989. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand. 79: 378-385.
24. Kumra S, Kranzler H, Gerbino-Rosen G, et al,. 2008. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 18: 307-316.
25. Leucht S, Komossa K, Rummel-Kluge C, et al,. 2009. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166: 152-163.
26. McEvoy JP, Lieberman JA, Stroup TS, et al,. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610.
27. Meltzer HY, Bobo WV, Roy A, et al,. 2008. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69: 274-285.
28. Meyers B,. 1978. Treatment of imipramine-resistant depression and lithium-refractory mania through drug interactions. Am J Psychiatry. 135: 1420-1421.
29. Mitchell M, Riesenberg R, Bari MA, et al,. 2006. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40mg/d oral olanzapine relative to 20mg/d oral olanzapine in stable psychiatric subjects. Clin Ther 28: 881-892.
30. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J,. 2000. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol. 20: 195-203.
31. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL,. 2002. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 159: 1146-1154.
32. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, et al,. 2003. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord. 73: 155-161.
33. Schaffer A, Levitt AJ, Joffe RT,. 2000. Mexiletine in treatment-resistant bipolar disorder. J Affect Disord 57: 249-253.
34. Scherk H, Pajonk FG, Leucht S,. 2007. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 64: 442-455.
35. Simpson GM, Angus JW,. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
36. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, et al,. 1991. Carbamazepine compared with lithium in the treatment of mania. J Affect Disord. 48: 915-921.
37. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W,. 1997. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73: 159-171.
38. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al,. 2005. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 66: 870-886.
39. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO,. 1992. Clozapine in the treatment of dysphoric mania. J Affect Disord. 32: 270-280.
40. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ,. 1999. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 156: 1164-1169.
41. Thomas P, Vieta E,. 2008. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat. 4: 675-686.
42. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al,. 1999. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 156: 702-709.
43. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al,. 2000. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 57: 841-849.
44. Tohen M, Chengappa KN, Suppes T, Zarate CA, Jr., Calabrese JR, Bowden CL, et al,. 2002. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 59: 62-69.
45. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, et al,. 2007. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 164: 1547-1556.
46. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, et al,. 2008a. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Am J Psychiatry. 192: 135-143.
47. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al,. 2008b. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 69: 1776-1789.
48. Volavka J, Czobor P, Sheitman B, et al,. 2002. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159: 255-262.
49. Young RC, Biggs JT, Ziegler VE, Meyer DA,. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.
50. Wolfsperger M, Greil W, Rossler W, Grohmann R,. 2007. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord. 99: 9-17.
51. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW,. 2002. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 63: 1148-1155.